Asciminib Roll-over Study

Abroad (travel likely)RecruitingPHASE4

Conditions

Chronic Myelogenous Leukemia · Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Michigan Med University of Michigan, Ann Arbor, Michigan, United States

    Contact: Study coordinator (Kelly Whitley) · kwhitley@med.umich.edu
    Contact: Principal Investigator (Moshe Talpaz)
  • Memorial Sloan Kettering, New York, New York, United States

    Contact: Study coordinator (Shakira Pascual) · pascuals@mskcc.org · 646-497-9068
    Contact: Principal Investigator (Michael Mauro)
  • Oregon Health Sciences University, Portland, Oregon, United States

  • Texas Oncology, Dallas, Texas, United States

    Contact: Study coordinator (Jessica Maner) · Jessica.Maner@usoncology.com · +1 214 370 1000
    Contact: Principal Investigator (Moshe Yair Levy)
  • Uni Of TX MD Anderson Cancer Cntr, Houston, Texas, United States

    Contact: Study coordinator (Susan Aline Wahl) · sawahl2@mdanderson.org · +1 713 792 2921
    Contact: Principal Investigator (Fadi Haddad)
  • Medical College of Wisconsin, Milwaukee, Wisconsin, United States

    Contact: Study coordinator (Esta Konkol) · ekonkol@mcw.edu · 414-805-6803
    Contact: Principal Investigator (Ehab Atallah)
  • Novartis Investigative Site, CABA, Buenos Aires, Argentina

  • Novartis Investigative Site, Capital Federal, Argentina

  • Novartis Investigative Site, Graz, Austria

  • Novartis Investigative Site, Vienna, Austria

  • Novartis Investigative Site, Rio de Janeiro, Rio de Janeiro, Brazil

  • Novartis Investigative Site, São Paulo, São Paulo, Brazil

  • Novartis Investigative Site, São Paulo, São Paulo, Brazil

  • Novartis Investigative Site, Varna, Bulgaria

  • Novartis Investigative Site, Montreal, Quebec, Canada

  • Novartis Investigative Site, Chongqing, Chongqing Municipality, China

  • Novartis Investigative Site, Guangzhou, Guangdong, China

  • Novartis Investigative Site, Zhengzhou, Henan, China

  • Novartis Investigative Site, Wuhan, Hubei, China

  • Novartis Investigative Site, Changchun, Jilin, China

  • Novartis Investigative Site, Xian, Shanxi, China

  • Novartis Investigative Site, Chengdu, Sichuan, China

  • Novartis Investigative Site, Beijing, China

  • Novartis Investigative Site, Beijing, China

  • Novartis Investigative Site, Shanghai, China

  • Novartis Investigative Site, Shenyang, China

  • Novartis Investigative Site, Tianjin, China

  • Novartis Investigative Site, Ostrava, Poruba, Czechia

  • Novartis Investigative Site, Brno, Czechia

  • Novartis Investigative Site, Copenhagen, Denmark

  • Novartis Investigative Site, Bordeaux, France

  • Novartis Investigative Site, Lyon, France

  • Novartis Investigative Site, Marseille, France

  • Novartis Investigative Site, Nantes, France

  • Novartis Investigative Site, Paris, France

  • Novartis Investigative Site, Vandœuvre-lès-Nancy, France

  • Novartis Investigative Site, Frankfurt am Main, Hesse, Germany

  • Novartis Investigative Site, Jena, Thuringia, Germany

  • Novartis Investigative Site, Berlin, Germany

  • Novartis Investigative Site, Kiel, Germany

  • Novartis Investigative Site, Milan, MI, Italy

  • Novartis Investigative Site, Roma, RM, Italy

  • Novartis Investigative Site, Naples, Italy

  • Novartis Investigative Site, Kobe, Hyōgo, Japan

  • Novartis Investigative Site, Beirut, Lebanon

  • Novartis Investigative Site, George Town, Pulau Pinang, Malaysia

  • Novartis Investigative Site, Johor Bahru, Malaysia

  • Novartis Investigative Site, Kuala Selangor, Malaysia

  • Novartis Investigative Site, Monterrey, Nuevo León, Mexico

  • Novartis Investigative Site, Khoudh, Oman

  • Novartis Investigative Site, Katowice, Poland

  • Novartis Investigative Site, Krakow, Poland

  • Novartis Investigative Site, Warsaw, Poland

  • Novartis Investigative Site, Wroclaw, Poland

  • Novartis Investigative Site, Lisbon, Portugal

  • Novartis Investigative Site, Porto, Portugal

  • Novartis Investigative Site, Timișoara, Romania

  • Novartis Investigative Site, Moscow, Russia

  • Novartis Investigative Site, Moscow, Russia

  • Novartis Investigative Site, Saint Petersburg, Russia

  • Novartis Investigative Site, Saint Petersburg, Russia

  • Novartis Investigative Site, Riyadh, Saudi Arabia

  • Novartis Investigative Site, Singapore, Singapore

  • Novartis Investigative Site, Uijeongbu-si, Gyeonggi-do, South Korea

  • Novartis Investigative Site, Busan, South Korea

  • Novartis Investigative Site, Jeollanam, South Korea

  • Novartis Investigative Site, Seoul, South Korea

  • Novartis Investigative Site, Santiago Compostela, A Coruna, Spain

  • Novartis Investigative Site, Badalona, Barcelona, Spain

  • Novartis Investigative Site, L'Hospitalet de Llobregat, Barcelona, Spain

  • Novartis Investigative Site, Bilbao, Bizkaia, Spain

  • Novartis Investigative Site, Santa Cruz, Santa Cruz De Tenerife, Spain

  • Novartis Investigative Site, Barcelona, Spain

  • Novartis Investigative Site, Barcelona, Spain

  • Novartis Investigative Site, Madrid, Spain

  • Novartis Investigative Site, Madrid, Spain

  • Novartis Investigative Site, Madrid, Spain

  • Novartis Investigative Site, Seville, Spain

  • Novartis Investigative Site, Valencia, Spain

  • Novartis Investigative Site, Taoyuan, Taiwan

  • Novartis Investigative Site, Samsun, Atakum, Turkey (Türkiye)

  • Novartis Investigative Site, London, United Kingdom

  • Novartis Investigative Site, Oxford, United Kingdom

  • Novartis Investigative Site, Hanoi, Vietnam

  • Novartis Investigative Site, Ho Chi Minh City, Vietnam

Study leads
  • Novartis Pharmaceuticals

    Study Director

    Novartis Pharmaceuticals